TS-141 30 mg | All Phenotypes | PM | IM | EM | UM | |
N | 29 | 1 | 2 | 25 | 1 | |
 Cmax (ng/mL) | 9.90 ± 11.6 | 57.1 | 24.9 ± 16.8 | 7.17 ± 4.66 | 1.06 | |
 AUC0-∞ (ng⋅h/mL) | arithmetic mean | 83.9 ± 138 | 728 | 213 ± 148 | 51.0 ± 35.1 | 4.69 |
geometric mean | 45.9 | 728 | 185 | 40.3 | 4.69 | |
CV (%) | 164 | – | 69.5 | 68.8 | – | |
 MRT0-∞ (h) | 11.8 ± 4.70 | 17.0 | 9.86 ± 0.764 | 11.8 ± 4.93 | 11.0 | |
Asverin 40 mg | All Phenotypes | PM | IM | EM | UM | |
N | 42 | 1 | 5 | 35 | 1 | |
 Cmax (ng/mL) | 30.7 ± 28.5 | 125 | 58.2 ± 26.2 | 24.9 ± 21.6 | 1.05 | |
 AUC0-∞ (ng⋅h/mL) | arithmetic mean | 114 ± 177 | 1080 | 248 ± 126 | 70.5 ± 57.9 | 3.62 |
geometric mean | 61.9 | 1080 | 220 | 51.6 | 3.62 | |
CV (%) | 155 | – | 50.8 | 82.2 | – | |
 MRT0-∞ (h) | 4.67 ± 1.67 | 12.3 | 5.76 ± 0.578 | 4.33 ± 1.13 | 3.54 |